SG11201606264SA - Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor - Google Patents

Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Info

Publication number: SG11201606264SA
Authority: SG; Singapore
Prior art keywords: plp; cofactor; pharmaceutical composition; dependent enzyme; erythrocytes encapsulating
Prior art date: 2014-02-12

Application number

SG11201606264SA

Inventor

Yann Godfrin

Vanessa Bourgeaux

Fabien Gay

Thomas Cortese

Original Assignee

Erytech Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-12

Filing date

2015-02-12

Publication date

2016-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606264S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-12 Application filed by Erytech Pharma filed Critical Erytech Pharma

2016-08-30 Publication of SG11201606264SA publication Critical patent/SG11201606264SA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01005—Tyrosine transaminase (2.6.1.5)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y404/00—Carbon-sulfur lyases (4.4)
- C12Y404/01—Carbon-sulfur lyases (4.4.1)
- C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Developmental Biology & Embryology (AREA)
Botany (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Rheumatology (AREA)

SG11201606264SA 2014-02-12 2015-02-12 Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor SG11201606264SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1451100A FR3017299B1 (en)	2014-02-12	2014-02-12	PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
PCT/EP2015/052962 WO2015121348A2 (en)	2014-02-12	2015-02-12	Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Publications (1)

Publication Number	Publication Date
SG11201606264SA true SG11201606264SA (en)	2016-08-30

Family

ID=50729647

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201606264SA SG11201606264SA (en)	2014-02-12	2015-02-12	Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
SG10201907367QA SG10201907367QA (en)	2014-02-12	2015-02-12	Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201907367QA SG10201907367QA (en)	2014-02-12	2015-02-12	Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Country Status (17)

Country	Link
US (3)	US10046009B2 (en)
EP (2)	EP3718562A1 (en)
JP (1)	JP6563958B2 (en)
KR (1)	KR102354103B1 (en)
CN (2)	CN111358941B (en)
AU (2)	AU2015217045B2 (en)
BR (1)	BR112016017337B1 (en)
CA (1)	CA2938469C (en)
CL (1)	CL2016002020A1 (en)
ES (1)	ES2808849T3 (en)
FR (1)	FR3017299B1 (en)
IL (1)	IL246941B (en)
JO (1)	JO3522B1 (en)
MX (1)	MX378781B (en)
RU (2)	RU2744659C2 (en)
SG (2)	SG11201606264SA (en)
WO (1)	WO2015121348A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11458170B2 (en)	2014-02-12	2022-10-04	Erytech Pharma	Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112016011195A2 (en)	2013-11-18	2017-09-19	Rubius Therapeutics Inc	ENUCLEATED ERYTHROID CELLS AND THEIR METHODS OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND THEIR USE, USE OF AN ERYTHROID CELL POPULATION, BIORACTOR, CELL MIXTURE AND MEDICAL DEVICE
US10869898B2 (en)	2014-04-01	2020-12-22	Rubius Therapeutics, Inc.	Methods and compositions for immunomodulation
EP3187190A1 (en) *	2015-12-31	2017-07-05	Erytech Pharma	Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
HRP20220147T1 (en)	2016-01-11	2022-04-15	Rubius Therapeutics, Inc.	PREPARATIONS AND PROCEDURES RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR INDICATIONS OF CANCER
US11576895B2 (en)	2016-01-11	2023-02-14	Epicentrx, Inc	Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
JP2019520342A (en)	2016-06-02	2019-07-18	サノフイＳａｎｏｆｉ	Conjugates of agents and moieties capable of binding to glucose sensing proteins
KR102869384B1 (en)	2017-07-07	2025-10-15	에피센트알엑스, 인코포레이티드	Composition for parenteral administration of therapeutic agents
EP3449935A1 (en) *	2017-08-31	2019-03-06	Erytech Pharma	Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
JP7176921B2 (en)	2017-10-19	2022-11-22	アンチキャンサーインコーポレーテッド	Preparations containing recombinant methioninase for cancer treatment, prevention and anti-aging
US20210170033A1 (en)	2017-12-01	2021-06-10	Sanofi	Novel conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein
WO2019164593A2 (en)	2018-01-08	2019-08-29	Epicentrx, Inc.	Methods and compositions utilizing rrx-001 combination therapy for radioprotection
US11541105B2 (en)	2018-06-01	2023-01-03	The Research Foundation For The State University Of New York	Compositions and methods for disrupting biofilm formation and maintenance
EP3880309A1 (en)	2018-11-15	2021-09-22	Erytech Pharma	Synergistic combinations of methionine depletion agents and immune checkpoint modulators
TW202106315A (en)	2019-04-26	2021-02-16	美商盧比亞斯治療公司	Compositions including enucleated erythroid cells
JP2022533252A (en)	2019-05-24	2022-07-21	ルビウスセラピューティクス，インコーポレイテッド	How to generate enucleated red blood cells
US20210130780A1 (en)	2019-11-04	2021-05-06	Rubius Therapeutics, Inc.	Methods of generating enucleated erythroid cells using myo-inositol
US20210147802A1 (en)	2019-11-04	2021-05-20	Rubius Therapeutics, Inc.	Methods of generating enucleated erythroid cells using taurine or hypotaurine
CA3178252A1 (en)	2020-05-11	2021-11-18	Erytech Pharma	Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
WO2022150578A1 (en)	2021-01-08	2022-07-14	Rubius Therapeutics, Inc.	Methods of treating a tumor in a human subject
WO2022150569A1 (en)	2021-01-08	2022-07-14	Rubius Therapeutics, Inc.	METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
TW202304482A (en)	2021-03-14	2023-02-01	美商盧比亞斯治療公司	Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
TW202313969A (en) *	2021-05-21	2023-04-01	美商克迪科思股份有限公司	Engineered methionine gamma lyase variants
TW202317179A (en)	2021-06-03	2023-05-01	美商盧比亞斯治療公司	Methods of treating hpv16-positive or hpv16-associated cancer in a subject
CN113481253B (en) *	2021-06-09	2022-05-24	连云港杰瑞药业有限公司	Method for preparing pyridoxal phosphate by biocatalysis
WO2023067200A1 (en)	2021-10-24	2023-04-27	Erytech Pharma	Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer
WO2025219395A1 (en)	2024-04-16	2025-10-23	Chu D'angers	Treatment of cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1354204A (en)	1963-01-22	1964-03-06	Auxiliaire De L Entpr Soc	Accident prevention device for loading skips, in particular for a concrete mixer
FR2529463B1 (en) *	1982-07-05	1986-01-10	Centre Nat Rech Scient	METHOD AND DEVICE FOR THE ENCAPSULATION IN ERYTHROCYTES OF AT LEAST ONE BIOLOGICALLY ACTIVE SUBSTANCE, IN PARTICULAR ALLOSTERIC EFFECTORS OF HEMOGLOBIN AND ERYTHROCYTES OBTAINED THEREBY
US5254572A (en) *	1987-11-27	1993-10-19	Vesta Medicines (Pty) Ltd.	Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5631271A (en) *	1986-11-29	1997-05-20	Serfontein; Willem J.	Methods and preparations for the treatment and prophylaxis of metabolic disturbances
WO1998040476A1 (en)	1997-03-13	1998-09-17	Shionogi & Co., Ltd.	PROCESS FOR PRODUCING L-METHIONINE η-LYASE CRYSTALS
US20020111310A1 (en) *	2000-10-06	2002-08-15	Rachel Meyers	25219, a novel human aminotransferase and uses therefor
KR20060065663A (en) *	2003-07-31	2006-06-14	안티캔서, 인코포레이티드	Use of PL in combination with PI-RTM ETA for improving efficacy in vivo
FR2873925B1 (en) *	2004-08-05	2006-10-13	Erytech Pharma Soc Par Actions	METHOD AND DEVICE FOR LYSE-RESCALING FOR THE INCORPORATION OF ACTIVE PRINCIPLE, IN PARTICULAR ASPARAGINASE OR INOSITOL HEXAPHOSPHATE, IN ERYTHROCYTES
FR2884717B1 (en) *	2005-04-25	2009-07-03	Erytech Pharma Soc Par Actions	ERYTHROCYTES CONTAINING ARGININE DEIMINASE
RU2362572C2 (en) *	2007-07-17	2009-07-27	Юрий Георгиевич Каминский	Way of depression of concentration of ammonia in blood by means of ammocytes and incapsulated glutamin synthetase
FR2919804B1 (en)	2007-08-08	2010-08-27	Erytech Pharma	COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
FR2925339B1 (en)	2007-12-24	2010-03-05	Erytech Pharma	DRUG FOR THE TREATMENT OF PANCREATIC CANCER
US20100316620A1 (en)	2008-02-13	2010-12-16	Vanessa Bourgeaux	Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease
FR2928270B1 (en)	2008-03-10	2011-01-21	Erytech Pharma	FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES
FR2938332B1 (en)	2008-11-07	2011-11-25	Erytech Pharma	PREDICTIVE TEST FOR NEUTRALIZATION OF ASPARAGINASE ACTIVITY
CN101429506A (en) *	2008-12-15	2009-05-13	吉林大学	Fish-in-net immobilized enzyme based on rubricyte carrier
FR2944106B1 (en)	2009-04-03	2012-09-28	Erytech Pharma	METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP).
CA2778669C (en)	2009-10-27	2019-04-16	Erytech Pharma	Composition to induce specific immune tolerance
KR20140145148A (en) *	2012-03-21	2014-12-22	에리테끄 파르마	Medicament for the treatment of acute myeloid leukemia (AML)
FR3005420B1 (en)	2013-05-07	2015-09-18	Erytech Pharma	METHOD OF STABILIZING SUSPENSIONS OF ERYTHROCYTES ENCAPSULATING AN ACTIVE INGREDIENT, SUSPENSIONS OBTAINED
EP2813234A1 (en)	2013-06-11	2014-12-17	Erytech Pharma	Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (en)	2014-02-12	2018-05-18	Erytech Pharma	PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
EP3187190A1 (en) *	2015-12-31	2017-07-05	Erytech Pharma	Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

2014
- 2014-02-12 FR FR1451100A patent/FR3017299B1/en not_active Expired - Fee Related
2015
- 2015-02-12 RU RU2019123935A patent/RU2744659C2/en active
- 2015-02-12 WO PCT/EP2015/052962 patent/WO2015121348A2/en not_active Ceased
- 2015-02-12 KR KR1020167022067A patent/KR102354103B1/en not_active Expired - Fee Related
- 2015-02-12 JO JOP/2015/0030A patent/JO3522B1/en active
- 2015-02-12 MX MX2016010235A patent/MX378781B/en unknown
- 2015-02-12 CA CA2938469A patent/CA2938469C/en active Active
- 2015-02-12 US US15/117,588 patent/US10046009B2/en active Active
- 2015-02-12 CN CN202010182496.4A patent/CN111358941B/en active Active
- 2015-02-12 SG SG11201606264SA patent/SG11201606264SA/en unknown
- 2015-02-12 EP EP20173043.9A patent/EP3718562A1/en active Pending
- 2015-02-12 BR BR112016017337-6A patent/BR112016017337B1/en not_active IP Right Cessation
- 2015-02-12 ES ES15705563T patent/ES2808849T3/en active Active
- 2015-02-12 RU RU2016133315A patent/RU2697086C2/en active
- 2015-02-12 CN CN201580007812.1A patent/CN106255506B/en not_active Expired - Fee Related
- 2015-02-12 AU AU2015217045A patent/AU2015217045B2/en not_active Ceased
- 2015-02-12 SG SG10201907367QA patent/SG10201907367QA/en unknown
- 2015-02-12 EP EP15705563.3A patent/EP3104875B1/en active Active
- 2015-02-12 JP JP2016568136A patent/JP6563958B2/en not_active Expired - Fee Related
2016
- 2016-07-25 IL IL246941A patent/IL246941B/en active IP Right Grant
- 2016-08-10 CL CL2016002020A patent/CL2016002020A1/en unknown
2018
- 2018-02-21 AU AU2018201237A patent/AU2018201237B2/en not_active Ceased
- 2018-08-13 US US16/102,171 patent/US10780126B2/en active Active
2020
- 2020-09-22 US US17/028,383 patent/US11458170B2/en active Active

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11458170B2 (en)	2014-02-12	2022-10-04	Erytech Pharma	Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor

Also Published As

Publication number	Publication date
FR3017299A1 (en)	2015-08-14
CA2938469C (en)	2023-03-14
CA2938469A1 (en)	2015-08-20
EP3104875B1 (en)	2020-05-06
ES2808849T3 (en)	2021-03-02
AU2018201237A1 (en)	2018-03-15
CN106255506A (en)	2016-12-21
CN111358941A (en)	2020-07-03
RU2019123935A (en)	2019-10-03
KR20160121532A (en)	2016-10-19
US20180344771A1 (en)	2018-12-06
JO3522B1 (en)	2020-07-05
US11458170B2 (en)	2022-10-04
IL246941B (en)	2019-09-26
WO2015121348A3 (en)	2015-10-08
JP2017506260A (en)	2017-03-02
AU2015217045B2 (en)	2018-03-08
KR102354103B1 (en)	2022-01-24
BR112016017337B1 (en)	2022-08-09
EP3104875A2 (en)	2016-12-21
SG10201907367QA (en)	2019-09-27
US10780126B2 (en)	2020-09-22
RU2697086C2 (en)	2019-08-12
RU2744659C2 (en)	2021-03-12
CL2016002020A1 (en)	2017-06-23
AU2015217045A1 (en)	2016-08-18
BR112016017337A2 (en)	2017-08-08
AU2018201237B2 (en)	2019-09-26
US20160361361A1 (en)	2016-12-15
WO2015121348A2 (en)	2015-08-20
RU2019123935A3 (en)	2020-03-26
US20210008114A1 (en)	2021-01-14
MX2016010235A (en)	2016-10-28
RU2016133315A3 (en)	2018-09-26
IL246941A0 (en)	2016-09-29
RU2016133315A (en)	2018-02-16
US10046009B2 (en)	2018-08-14
JP6563958B2 (en)	2019-08-21
CN106255506B (en)	2020-04-14
FR3017299B1 (en)	2018-05-18
CN111358941B (en)	2023-12-01
EP3718562A1 (en)	2020-10-07
MX378781B (en)	2025-03-11

Publication	Publication Date	Title
IL246941A0 (en)	2016-09-29	Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
EP3143134A4 (en)	2017-10-18	Modified natural killer cells and uses thereof
EP3240552A4 (en)	2018-06-20	Natural killer cells and uses thereof
EP3149036A4 (en)	2017-12-27	Anti-cd20 glycoantibodies and uses thereof
EP3178504A4 (en)	2018-05-09	Package and package assembly
EP3134824A4 (en)	2018-03-28	Enhancing reading accuracy, efficiency and retention
EP3309856A4 (en)	2018-12-19	Battery and assembled battery
EP3203096A4 (en)	2018-10-10	Bearing and bearing pad
EP3191578A4 (en)	2018-06-20	Cells expressing apolipoprotein e and uses thereof
LT3131577T (en)	2020-07-27	Modified host cells and uses thereof
EP3170528A4 (en)	2018-03-21	Micro-needle and micro-needle assembly
EP3213769A4 (en)	2018-02-21	Transdermal-absorption-promoter and transdermal-absorption-promoting supplement
IL247978A0 (en)	2016-11-30	Modified sulfamidase and production thereof
EP3288570A4 (en)	2018-11-21	Modified stem cells and uses thereof
EP3185873A4 (en)	2018-05-02	Pharmaceutical composition and methods
EP3182988A4 (en)	2018-05-23	Disintegrin variants and pharmaceutical uses thereof
EP3205416A4 (en)	2018-04-25	Titanium encapsulation structure and titanium material
EP3194176A4 (en)	2018-05-30	Linerless record material
EP3187062A4 (en)	2018-04-25	Shoe-formation member and shoe
EP3190116A4 (en)	2018-04-04	Pyrazolothiazole compound and medicine
EP3221210A4 (en)	2018-07-18	Track pads and track assembly
IL250272A0 (en)	2017-03-30	Aglycosylated enzyme and uses thereof
EP3385577A4 (en)	2019-07-03	Shaft and seal structure
EP3134424A4 (en)	2018-03-14	Biomass extracts and methods thereof
HK1261250A1 (en)	2019-12-27	Modified immune cells and uses thereof

SG11201606264SA - Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=50729647

Family Applications (2)

Family Applications After (1)

Country Status (17)

Cited By (1)

Families Citing this family (26)

Family Cites Families (23)

Cited By (1)

Also Published As

Similar Documents